Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias

PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

July 31, 2022

Study Completion Date

May 31, 2023

Conditions
AngiodysplasiaVascular MalformationsGastrointestinal HemorrhageAnemia
Interventions
DRUG

Octreotide

Two injections of 20 mg will be given monthly.

Trial Locations (12)

7334 DZ

Gelre Hospital, Apeldoorn

6525GA

Radboud University Medical Center (Radboudumc), Nijmegen

5200 ME

Jeroen Bosch Hospital, 's-Hertogenbosch

5623 EJ

Catharina Hospital, Eindhoven

5022 GC

Elisabeth-TweeSteden Hospital, Tilburg

2625 AD

Reinier de Graaf Gasthuis, Delft

3430 EM

St. Antonius Hospital, Nieuwegein

6815AD

Rijnstate Hospital, Arnhem

9713GZ

University Medical Center Groningen (UMCG), Groningen

8441 PW

Tjongerschans Hospital, Heerenveen

Unknown

Maasstad Hospital, Rotterdam

5406 PT

Bernhoven Hospital, Uden

All Listed Sponsors
collaborator

Jeroen Bosch Ziekenhuis

OTHER

collaborator

Elisabeth-TweeSteden Ziekenhuis

OTHER

collaborator

Catharina Ziekenhuis Eindhoven

OTHER

collaborator

Bernhoven Hospital

OTHER

collaborator

Tjongerschans hospital

UNKNOWN

collaborator

Gelre Hospitals

OTHER

collaborator

Maasstad Hospital

OTHER

collaborator

Reinier de Graaf Groep

OTHER

collaborator

University Medical Center Groningen

OTHER

collaborator

Rijnstate Hospital

OTHER

collaborator

St. Antonius Hospital

OTHER

lead

Radboud University Medical Center

OTHER

NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias | Biotech Hunter | Biotech Hunter